{"id":48361,"date":"2026-08-13T16:39:46","date_gmt":"2026-08-13T11:09:46","guid":{"rendered":"https:\/\/www.editage.com\/insights\/?p=48361"},"modified":"2026-08-13T16:45:48","modified_gmt":"2026-08-13T11:15:48","slug":"eu-mdr-and-the-evolving-standard-for-clinical-evidence","status":"publish","type":"post","link":"https:\/\/www.editage.com\/insights\/eu-mdr-and-the-evolving-standard-for-clinical-evidence","title":{"rendered":"EU MDR and the evolving standard for clinical evidence in medical devices"},"content":{"rendered":"\n

Summary: <\/strong>The European Union Medical Device Regulation (EU MDR) has introduced significant changes to medical device approval. This article takes a closer look at the EU MDR to understand its implications for manufacturers, the compliance challenges it has created, and how clinical evidence is now more than a regulatory requirement.<\/p>\n\n\n\n

Table of Contents<\/strong><\/a><\/strong><\/p>\n\n\n\n

The shift in medical device regulations in Europe<\/a><\/p>\n\n\n\n

Beyond compliance: The broader role of the EU MDR<\/a><\/p>\n\n\n\n

Challenges in implementing the EU MDR<\/a><\/p>\n\n\n\n

A shortage of authorized certification bodies<\/a><\/p>\n\n\n\n

A narrower pathway for legacy devices<\/a><\/p>\n\n\n\n

Preparing the Clinical Evaluation Report (CER)<\/a><\/p>\n\n\n\n

How the industry is responding<\/a><\/p>\n\n\n\n

Frequently Asked Questions<\/a><\/p>\n\n\n\n

References<\/a><\/p>\n\n\n\n

The shift in medical device regulations in Europe<\/a><\/h1>\n\n\n\n

Medical device regulation in Europe took shape in the early 1990s, when the Medical Device Directive (93\/42\/EEC)<\/a> established a common framework for medical device market access across member states. For most of the two decades that followed, manufacturers navigated a system centered on technical documentation and process compliance. However, the European Union Medical Device Regulation (Regulation EU 2017\/745)<\/a>, commonly referred to as the EU MDR, changed this framework considerably.<\/p>\n\n\n\n

Adopted in 2017 and applied fully from May 2021, the EU MDR replaced the previous Medical Device Directive (MDD) and the Active Implantable Medical Device Directive (AIMDD)<\/a> with a more stringent framework. The EU MDR aims to improve patient safety, strengthen clinical evidence requirements, and increase transparency. These objectives are pursued through stricter clinical evaluation standards; more rigorous post-market surveillance; and the European Database on Medical Devices (EUDAMED)<\/a> for device registration, certification data, and post-market outcomes.<\/p>\n\n\n\n

Beyond compliance: The broader role of the EU MDR<\/a><\/h1>\n\n\n\n

The EU MDR outlines advanced patient safety provisions. Manufacturers are now required to demonstrate clinical safety and performance<\/a> by collecting post-market clinical data, which was not a clearly defined requirement under the MDD. This means that claims about a device\u2019s intended use and clinical benefits must be supported by verifiable evidence. By centralizing post-market data on adverse events, EUDAMED is likely to improve patient safety detection<\/a> over the long term.<\/p>\n\n\n\n

The implications of the EU MDR extend beyond the regulatory function. Hospital procurement teams now expect scientific justification before investing in new technologies. Clinicians look more closely at published evidence before adopting new devices. Investors assess regulatory readiness when looking for potential commercial risks. As a result, the strength of a manufacturer\u2019s clinical evidence shapes how its products are received by regulators, clinicians, and investors alike.<\/p>\n\n\n\n

Challenges in implementing the EU MDR<\/a><\/h1>\n\n\n\n

The practical implementation of the EU MDR has introduced some challenges.<\/p>\n\n\n\n

A shortage of authorized certification bodies<\/a><\/h2>\n\n\n\n

Notified bodies<\/a> are organizations authorized by EU member states to assess device conformity and issue Conformit\u00e9 Europ\u00e9enne (CE) certificates. A study<\/a> on EU MDR revealed that of the 56 previously designated notified bodies under the earlier directives, only 20 had received MDR designation by the time the regulation came into full effect. This is attributed to stricter qualification requirements placed on notified bodies.<\/p>\n\n\n\n

Fewer designated bodies, combined with a large volume of concurrent submissions, produced a certification backlog. As a result, the European Commission had to extend deadlines multiple times, with transition periods for certain device categories running through 2027 and 2028. These extensions eased immediate pressure without resolving the underlying capacity constraint. The European Commission\u2019s 2025 Economic Operator Survey<\/a> found that many medical device manufacturers had only partially transitioned their portfolios and a large number reported they had discontinued one or more devices. This placed low-volume, niche, and legacy products at highest risk.<\/p>\n\n\n\n

A narrower pathway for legacy devices<\/a><\/h2>\n\n\n\n

The second challenge is more structural. Under the MDD, many manufacturers demonstrated safety and effectiveness by citing equivalence to an existing product in the published literature. Under the EU MDR and the MDCG 2020-5 guidance<\/a> issued under it, claiming equivalence to another manufacturer\u2019s equivalent device now requires a formal contractual agreement granting continuous access to that manufacturer\u2019s technical documentation \u2013 an arrangement competing manufacturers rarely agree to. This means that for legacy device portfolios, manufacturers must either generate new primary clinical evidence or, where producing this evidence is not commercially viable, withdraw those products from the EU market. Under the EU MDR, equivalence claims that previously met the MDD standard are increasingly found to be insufficient<\/a> by notified bodies, and legacy devices are often required to be supported by new clinical data or updated indications.<\/p>\n\n\n\n

Preparing the Clinical Evaluation Report (CER)<\/a><\/h2>\n\n\n\n

Under the EU MDR, medical device manufacturers now need to produce stronger, more independently generated clinical evidence and present it in a Clinical Evaluation Report (CER)<\/a>. The CER must:<\/p>\n\n\n\n